🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — cardiovascular outcomes arm Page 3

Orforglipron ATTAIN-4 — cardiovascular outcomes arm

TrialTracker_MD Mon, May 25, 2026 at 7:53 AM 21 replies 544 viewsPage 3 of 5
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
May 26, 2026 at 3:19 AM#11
Dr.MetabolicMD said:
The manufacturing argument is the underrated one.

Bookmarking. The distinction being drawn above is the one nobody else makes.

32 7NeuroNate, JessicaH_TX, KevinCompounds and 29 others
Reply Quote Save Share Report
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
May 26, 2026 at 2:53 PM#12

Clinical perspective, offered as context rather than as advice. Start from the measurement rather than the conclusion. Almost every disagreement here turns out to be two people measuring different things and comparing the numbers anyway.

Last edited: May 26, 2026 at 6:53 PM
31 6ricardo_MIA, BrianDallas92, labquiet_amy and 28 others
Reply Quote Save Share Report
Dr.KarenChen
VIP Member
4,210
24,567
Nov 2023
San Francisco, CA
May 27, 2026 at 2:27 AM#13
anders_CPH said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

I read this differently from anders_CPH, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

30 5TomFromTexas, mike.trainer_LA, sarah_nash92 and 27 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
May 27, 2026 at 2:01 PM#14

One concrete data point for the thread. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

29 4hans_munich, jason_sac26, chris_chi24 and 26 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
May 28, 2026 at 1:35 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part.

28 3PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 25 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register